Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E2YL
|
|||
| Former ID |
DIB002406
|
|||
| Drug Name |
UNI-rhIL-11
|
|||
| Synonyms |
Recombinant human interleukin 11 (thrombocytopenia), Uni-Bio Science Group; RhIL-11 (thrombocytopenia), Uni-Bio Science Group
Click to Show/Hide
|
|||
| Indication | Thrombocytopenia [ICD-11: 3B64] | Phase 3 | [1] | |
| Company |
Uni-Bio Science Group Limited
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 11 receptor alpha (IL11RA) | Target Info | Modulator | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Panther Pathway | Interleukin signaling pathway | |||
| WikiPathways | Interleukin-11 Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01663441) A Phase Study of Genetically Modified Recombinant Human Interleukin-11. U.S. National Institutes of Health. | |||
| REF 2 | Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia. Ai Zheng. 2002 Aug;21(8):892-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.